.jpg)
Dr. Yanglem Ajitkumar Singh
Regional Institute of Medical Sciences, IndiaTitle: Efficacy of Single Dose of Misoprostol 800?g in the First Trimester Termination of Pregnancy- A Cross Sectional Study
Abstract
Background: The MTP (Amendment) Act
2021 has allowed termination of pregnancy up to 24 weeks on only certain
indications. Decision of two medical practitioners are required for termination
beyond 20 weeks. Misoprostol is one drug used for medical termination of
pregnancy. It can be used alone in single or multiple doses, or in combination
with other drugs. The study was undertaken to determine the efficacy of a
single dose of 800 μg of misoprostol in the first trimester pregnancy
termination.
Methods: It was a cross-sectional study
conducted among 124 women in the first trimester who were undergoing
termination of pregnancy. After administering 800 μg of misoprostol vaginally,
participants were kept under observation for 48 hours. Data were collected and
analysed.
Results: Around half of the
participants (56.4%) expelled the conceptus completely by 12 hours, 78.2% by 48
hours. Seven (5.6%) out of those 27 failed cases were given further doses of
misoprostol, while in the remaining 20 (16.1%), surgical intervention was
undertaken.
Conclusions: The efficacy of a single
dose of misoprostol for 1st trimester termination of pregnancy varies widely
from study to study, but, the efficacy increases with adding further doses of
the same drug or addition of mifepristone. Misoprostol is a safe, cost
effective, and reasonable drug for the termination of pregnancy in first
trimester.
Keywords: abortion, misoprostol, termination.
Biography
Dr. Yanglem Ajitkumar Singh is an MD- Obstetrics and
Gynaecology. He is also a fellow in Gynaecological Oncology. Currently, he is
serving as an assistant professor in the department of Obstetrics and
Gynaecology, Regional Institute of Medical Sciences, Imphal, India.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
midwifery@scientexconferences.com
General Queries
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
neonatalcare@scientexevents.com
Our Social Presence
Call us at
USA :+1 (689) 267 3738